Asian alcoholics. This case-control study of whether the enzyme-related vulnerability for esophageal cancer can be extended to a general population involved 234 Japanese men with esophageal squamous cell carcinoma and 634 cancer-free Japanese men who received annual health checkups. The GSTM1 genotype was not associated with the risk for this cancer. Light drinkers (1-8.9 units/week) with ALDH2*1/2*2 had an esophageal cancer risk 5.82 times that of light drinkers with ALDH2*1/2*1 (reference category), and their risk was similar to that of moderate drinkers (9-17.9 units/week) with ALDH2*1/2*1 (odds ratio ⍧ 5.58). The risk for moderate drinkers with ALDH2*1/2*2 (OR ⍧ 55.84) exceeded that for heavy drinkers (18⍣ units/week) with ALDH2*1/2*1 (OR ⍧ 10.38). Similar increased risks were observed for those with ADH2*1/2*1. A multiple logistic model including ALDH2, ADH2, and ADH3 genotypes showed that the ADH3 genotype does not significantly affect the risk for esophageal cancer. For individuals with both ALDH2*1/ 2*2 and ADH2*1/2*1, the risk of esophageal cancer was enhanced in a multiplicative fashion (OR ⍧ 30.12), whereas for those with either ALDH2*1/2*2 or ADH2*1/2*1 alone the ORs were 7.36 and 4.11. In comparison with the estimated population-attributable risks for preference for Abbreviations: ALDH, aldehyde dehydrogenase; ADH, alcohol dehydrogenase; CI, confidence interval. GSTM1, glutathione S-transferase M1; OR, odds ratio; PAR, population-attributable risk.
Introduction
Since our first report in 1996 (1), studies of various Japanese (1) (2) (3) (4) (5) (6) and Chinese (7) heavy-drinking populations have shown that the inactive aldehyde dehydrogenase (ALDH)-2 encoded by the ALDH2*1/2*2 genotype is a strong risk factor for esophageal cancer. ALDH2 is a key enzyme in the elimination of acetaldehyde, which is generated by alcohol metabolism (8) . The evidence points to a critical role for acetaldehyde, an established animal carcinogen (9, 10) , in cancerization of the human esophagus.
In persons with ALDH2*2, a mutant allele that is prevalent in east Asians, ALDH2 is inactive. Inactive ALDH2 generally inhibits East Asians from heavy drinking by causing acetaldehydemia and alcohol flushing responses, which include facial flushing, tachycardia and drowsiness (11) . However, the preventive effect of heterozygous ALDH2*1/2*2 is incomplete and influenced by sociocultural factors. Recent decades have seen a dramatic increase in the proportion of heavy drinkers who have inactive heterozygous ALDH2. More specifically, 2.5% of Japanese alcoholics in 1979, 8 .0% in 1986 and 13.0% in 1992 had the inactive heterozygous ALDH2 (12) . The paradoxical combination of heavy drinking and the gene that makes individuals susceptible to alcohol is most hazardous with regard to esophageal cancer; thus, heavy drinking by ALDH2 heterozygotes should be taken more seriously.
Some attention has been focused on the mechanisms through which drinkers with inactive ALDH2 overcome acetaldehydemia and alcohol flushing. Drinking is important in Japanese business culture. Occasionally getting drunk is much more acceptable to Japanese men than to American men of Japanese ancestry (13) . Under the influence of these drinking customs, the flushing response diminishes in intensity in males with long or heavy drinking histories. Among Japanese ALDH2 heterozygotes, 77.0% of all men over 50 years of age (14) and 71.5% of alcoholic males with esophageal cancer (15) reported alcohol flushing currently or during the first to second year after they started drinking. However, only 64.6% and 8.2% of these two groups reported 'current alcohol flushing.' These negative changes in the flushing responses suggest that heavy drinkers develop tolerance to severe acetaldehydemia.
That tolerance may enhance their vulnerability to heavy drinking and alcohol-induced cancers.
Like ALDH2, alcohol dehydrogenase (ADH)-2 is polymorphic, and its mutant ADH2*2 allele is highly prevalent among east Asians. Although the ALDH2 genotype, but not the ADH2 genotype, determines an individual's peak blood acetaldehyde concentration (16) , the ADH2*2 allele encodes a superactive subunit of ADH2, and superactive ADH2*2 homodimers have about 40 times higher Vmax than the less active ADH2*1/2*1 form of ADH2 (8) . ADH2*1/2*1 has been consistently demonstrated to enhance the risk for esophageal cancer in East Asian drinkers (2, 5, 7, 15) . Among alcoholics, the ALDH2*1/2*2 and ADH2*1/2*1 gene combination enhanced the risk for esophageal cancer in a multiplicative fashion (7, 15) .
In fact, 52% of alcoholic men with esophageal cancer who have both the ALDH2*1/2*2 and the ADH2*1/2*1 genotypes reported 'never alcohol flushing' (15) . The flushing response may be triggered by an initially steep rise in blood acetaldehyde after drinking. This dramatic change may not occur in persons with the much less active form of ADH2, in spite of the presence of inactive heterozygous ALDH2. Local enzyme activities in the skin might affect alcohol flushing, as suggested by cutaneous flushing induced by the ethanol patch test (17) . Ethanol patch test results differ by ADH2 genotype (18) . Regardless of the mechanism affecting alcohol flushing, individuals with this gene combination should be considered at the highest risk for esophageal cancer, because, as a result of their lack of protective alcohol flushing, they are likely to become heavy drinkers, and to be exposed to higher levels of acetaldehyde.
Among western populations, ADH3 gene polymorphism is the rate-limiting factor in acetaldehyde metabolism (8) . Enzymes encoded by the ADH3*1 allele produce acetaldehyde twice as fast as those encoded by the ADH3*2 allele (8) . Individuals possessing ADH3*1 are hypothesized to be at greater risk for alcohol-related cancer. Although published studies have not yielded a consistent pattern of association (19) (20) (21) (22) (23) (24) , several have suggested that individuals who have ADH3*1/3*1 are at greater risk for upper aerodigestive tract cancer when there is very high, chronic alcohol exposure (19, 20, 24) . It has been consistently reported that in East Asians the ADH3*2 allele enhances the risk of alcoholism through linkage with the ADH2*1 allele (25) (26) (27) .
Whether the enzyme-related vulnerability for esophageal cancer can be extended to light to moderate drinkers is a very important issue needing immediate attention because of its potential role in the prevention of cancer in the general Japanese population. Among populations of European origin, light to moderate drinking has demonstrated health benefits, i.e. protection against heart disease and stroke (28) . Although there are a few reports showing a similar trend (29, 30) , it has yet to be evaluated whether this is the case for east Asians.
Proof that certain combinations of ALDH2, ADH2 and ADH3 genotypes markedly increase the risk for esophageal cancer among light-to moderate-drinking populations could change our views on the beneficial health effects of light to moderate drinking. Therefore, to shed more light on the overall risk for esophageal cancer, we designed a multi-institutional case-control study to determine the relative impact of combinations of alcohol-metabolizing enzymes, drinking behavior and other environmental factors, including smoking and a diet poor in vegetables and fruit. By broadening the concept of what 1852 constitutes high-risk drinking, we may adopt a new strategic approach aimed at the prevention of esophageal cancer.
Glutathione S-transferase M1 (GSTM1) is a multifunctional enzyme that detoxifies toxic and carcinogenic electrophiles in tobacco smoke (31) . Individuals with the GSTM1 deletion genotype (0/0) may have an impaired ability to detoxify carcinogenic compounds and may be at increased risk for certain smoking-related cancers (31) . The results of several Asian studies using middle-sized samples (164-296) to test this hypothesis regarding esophageal cancer were mixed (2, (32) (33) (34) (35) . Inasmuch as the risk conferred to individuals with the GSTM1 deletion genotype appears to be small (31) , study size is critical to reliable estimation of cancer risk. Therefore, in this larger study, we also examined the association between GSTM1 genotype and esophageal cancer susceptibility.
Materials and methods
The case participants in this study were 234 male Japanese patients with primary esophageal squamous cell carcinomas treated at the National Cancer Center Hospital, the National Cancer Center Hospital East, Kawasaki Municipal Hospital, or the National Osaka Hospital. All were registered between September 2000 and December 2001 and met the following inclusion criteria: (a) ages between 40 and 79 years and (b) esophageal squamous cell carcinomas newly diagnosed by histology within 3 years of registration. We excluded from this study alcoholic patients diagnosed as having esophageal cancer at the National Institute on Alcoholism, Japan (5) and esophageal cancer patients registered in our previous study between 1998 and 1999 (58) . Only two of 236 cases fully informed of the purpose of the study refused to participate. The controls consisted of cancer-free men who visited two Tokyo clinics for annual health checkups between September 2000 and December 2001. Most of the controls were ordinary residents or workers living in Tokyo or neighboring areas, who had been registered in the lists of the clinics for annual health checkups. Potentially eligible subjects were sent letters of invitation and then contacted at the clinics. Eighty-six percent of the eligible subjects contacted were enrolled in the study, yielding a total of 634 controls.
The ethics committee of each collaborating institution reviewed and approved the proposed study, and each of the participants gave informed consent.
Each participant independently completed a structured questionnaire concerning his drinking, smoking, and dietary habits; those with cancer were instructed to report on their habits before they got sick. Each was asked to classify himself as a never drinker, a current drinker, or an ex-drinker, and to report alcohol intake as the frequency of consumption and the usual amount(s) and type(s) of alcoholic beverage(s) consumed. The frequency of consumption was divided into five categories: never; 1-3 days/month; 1-2 days/week; 3-4 days/week, and 5 or more days/week. The weekly frequency for drinking was calculated according to a score assigned to each frequency category (0, 0.5, 1.5, 3.5, and 6, respectively). Weekly ethanol consumption was calculated using a standard conversion for alcoholic beverages in which 180 ml sake was considered to be 22 g ethanol; 180 ml shochu, 36 g; 633 ml beer, 25 g; 30 ml whiskey, 10 g; and 120 ml wine, 11 g. Weekly alcohol intake was then converted into the number of units per week by dividing the total ethanol consumption in grams by 22 g per unit (the ethanol content of one serving of sake). The subjects were classified as never/rare drinkers, ex-drinkers, or current drinkers who consumed 1-8.9 units/week (light drinkers), 9-17.9 units/week (moderate drinkers), or 18ϩ units/week (heavy drinkers). The questionnaire also asked about the frequency of drinking strong alcoholic beverages straight. In addition, the subjects reported on smoking and the frequency of their intake of green and yellow vegetables and fruit as well as their preference for high-temperature food. The intake frequency of green and yellow vegetables and fruit was respectively asked using five categories: seldom; 1-2 days/month; 1-2 days/week; 3-4 days/week, and almost every day.
Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) methods or a PCR method were performed on lymphocyte DNA samples from all participants, without knowledge of cancer status, to determine the genotypes for ALDH2 (5, 36) , ADH2 (37), ADH3 (37) , and GSTM1 (38) .
Fisher's exact test and the Mantel-Haenszel chi-square test were used in comparing group statistics. The associations between ALDH2, ADH2, ADH3, and GSTM1 genotypes and esophageal cancers were expressed in terms of the odds ratio (OR) and the population-attributable risk (PAR; 
Results
Description of the subjects by age, drinking, smoking, and dietary habits (Table I ) revealed that the esophageal cancer patients were significantly older than the cancer-free controls.
After adjustment for age, we observed that the cancer patients reported more drinking, more drinking of strong beverages, more smoking, lower intake of green and yellow vegetables, lower intake of fruit, and higher preference for hightemperature food than the controls. However, the preference for high-temperature food did not differ between the two groups after adjustments for age and drinking and smoking habits. The cases and controls differed significantly in the distribution of ALDH2, ADH2, and ADH3 genotypes, but they were similarly distributed across GSTM1 genotypes (Table II) . After adjustment for age and drinking habits, we found that the frequency of the GSTM1 deletion genotype did not differ significantly between the cases and controls for either heavy smokers, defined as 30 or more pack years, 41.4% (n ϭ 72/174) vs. 51.2% (n ϭ 146/285), adjusted OR ϭ 0.65 (95% CI: 0.41-1.03), respectively, and those with Ͻ30 pack years of smoking, 51.7% (n ϭ 31/60) vs. 50.1% (n ϭ 175/349), adjusted OR ϭ 1.03 (0.53-1.98), respectively.
After adjusting for age, the frequency of drinking strong beverages, smoking, and the intake of green and yellow vegetables and fruit, we estimated the risk for esophageal cancer in five drinking categories (never/rare, light, moderate, heavy, and ex-drinkers) by ALDH2, ADH2, and ADH3 genotypes, respectively (Table III) . Because there were no never/ rare drinkers among the cancer patients with active ALDH2, we used light drinkers with active ALDH2 as our reference category.
For light drinkers with inactive heterozygous ALDH2 the risk for esophageal cancer was 5.82-fold the risk for light drinkers with active ALDH2 -a high risk compared with that for moderate drinkers with active ALDH2 (OR ϭ 5.58). The risk for esophageal cancer in moderate drinkers with the inactive ALDH2 (OR ϭ 55.84) exceeded that of heavy drinkers with active ALDH2 (OR ϭ 10.38). Significantly increased risks for esophageal cancer in subjects with ALDH2*1/2*2 were found throughout all but the never/rare drinking category (ORs ϭ 5.73-10.01). Similar increased risks were estimated for those with the ADH2*1/2*1 genotype. As for the ADH3 genotype, a significantly higher risk for esophageal cancer was calculated for moderate to heavy drinkers with the ADH3*1/3*2 or ADH3*2/3*2 genotype compared with the risk for subjects with the ADH3*1/3*1 genotype. ADH2 and ADH3 gene polymorphisms, not only for the cancer patients (D ϭ 0.044, χ 2 ϭ 39.1, df ϭ 1, P Ͻ 0.0001) but for the controls (D ϭ 0.022, χ 2 ϭ 38.6, df ϭ 1, P Ͻ 0.0001).
The haplotype including the ADH2*1 and ADH3*2 alleles was over represented among both the cancer patients and controls. The frequencies of estimated haplotypes were significantly different between the cancer patients and controls (Table IV) . The proportion of haplotypes that included ADH2*1 1854 allele was higher in the cancer patients than in controls regardless of the accompanied ADH3 allele. By contrast, the proportion of haplotypes that included ADH3*2 allele was similar between the cancer patients and controls when the accompanied ADH2 allele was identical. A multiple logistic model including ALDH2, ADH2, and ADH3 genotypes showed that the ALDH2*1/2*2 (OR ϭ 7.46) and ADH2*1/2*1 (OR ϭ 4.11) genotypes were strongly associated with the risk for esophageal cancer, but that the ADH3 genotype exerted no significant effect on it (Table V) . For individuals with both ALDH2*1/2*2 and ADH2*1/2*1, the risk for esophageal cancer was enhanced in a multiplicative fashion (OR ϭ 30.12), whereas for those with either ALDH2*1/ 2*2 or ADH2*1/2*1 alone, the ORs were 7.36 and 4.11, respectively (Table VI) .
Estimation of PAR for each of the individual and combined esophageal cancer risk factors under study (Table VII) revealed that alcohol drinking was the one with the greatest impact (PAR ϭ 90.9%). Alcohol drinking in ALDH2 heterozygotes accounted for 68.5% of the esophageal cancer cases. The PARs for the preference for strong alcoholic beverages, smoking, lower intake of green and yellow vegetables, and lower intake of fruit were 30.7, 53.6, 25.7, and 37.6%, respectively. Together, these risk factors accounted for 98.1% of the cases of esophageal cancer.
Discussion
The most crucial information obtained from this study is that ALDH2-related vulnerability for esophageal cancer includes not only heavy drinkers but also light-to-moderate drinkers. Among our study participants, light drinking posed a higher risk for esophageal cancer in individuals with inactive heterozygous ALDH2 than in those with active ALDH2 -a risk compatible with the higher risk for moderate drinkers with active ALDH2. Similarly, the risk for moderate drinkers with inactive ALDH2 exceeded that for heavy drinkers with active ALDH2.
In contrast to the long-held belief that the risk for alcohol- related esophageal cancer increases in dose-dependent fashion (40, 41) , our new findings show the difference between risks for drinkers with and without inactive ALDH2. An alcohol challenge test showed that in ALDH2 heterozygotes the average peak blood acetaldehyde after drinking a small amount of ethanol (0.1 g/kg body wt) was five times the average peak blood acetaldehyde in active ALDH2 homozygotes after drinking a moderate amount of ethanol (0.8 g/kg body wt; 42). Thus, with regard to the ALDH2 genotype, the levels of acetaldehyde in blood may determine dose dependency after drinking. Although multivariate analysis showed a significantly increased risk for esophageal cancer in the presence of the ALDH2*2/2*2 genotype, the small number of cases with the ALDH2*2/2*2 genotype in this study prevents reaching any conclusion. These findings may force changes in our long-held views of Japanese men's risky drinking, but confirmation of these associations is needed. One recent study (6) reported enhanced risk for esophageal cancer due to the inactive heterozygous ALDH2 in heavy drinkers (OR ϭ 16.4), but the risk did not reach significance in non-heavy drinkers (OR ϭ 1.7). That study's non-heavy-drinking cancer population consisted of 34 cases, of which 16 were female. Its small sample size and the inclusion of women might have hampered that study from obtaining significant results. Analysis of women's risk for esophageal cancer is another focus of ongoing research in our laboratories.
There is ample evidence of acetaldehyde's carcinogenicity in experimental animals (9, 10) . In addition, the levels of acetaldehyde-DNA adducts are higher in leukocytes from alcoholics than in those from healthy controls (43) , and chromosomal alterations are observed more frequently in lymphocytes from drinkers with inactive ALDH2 (44). It is reasonable to speculate, therefore, that the high risk for esophageal cancer in persons with inactive ALDH2 is the consequence of repeated exposure to acetaldehyde. Individuals with inactive ALDH2 are incapable of rapidly eliminating this carcinogenic compound after drinking ethanol. The reason for the selective influence of acetaldehyde on the esophagus is still open to question, however. This influence may be related to the rate of ethanol metabolism by topical mucosal enzymes in the esophagus (45) . High-Km ADH7 is strongly expressed in the esophagus, which is active in producing acetaldehyde upon exposure to a locally high dose of ethanol. Moreover, salivary acetaldehyde levels are high after a moderate dose of alcohol in individuals with the ALDH2*2 allele (46). Alcoholic beverages themselves contain high levels of acetaldehyde (47) , and normal oral microflora also form acetaldehyde from ethanol and contribute to acetaldehyde levels in saliva (48) .
The esophagus lacks ALDH2 activity or expresses it extremely weakly, if at all (45) . After exposure to acetaldehyde derived from systemic, mucosal, salivary or bacterial production, and alcoholic beverages per se, inefficient degradation of the acetaldehyde in the esophagus may enhance the risk for cancer. Comparison between the acetaldehyde concentrations in the esophagus and other organs would provide information crucial to the elucidation of this issue.
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Although overall trends suggest that all types of alcoholic beverages increase the risk for esophageal cancer, some epidemiologic studies have shown stronger associations between esophageal cancer and alcoholic beverages high in ethanol (40) . The present multivariate analyses confirm our earlier reports that alcoholic Japanese men's risk for esophageal cancer increases significantly with the use of strong alcoholic beverages (49, 50) . Our results stress not only the importance of the local effect of ethanol and its solvent action on tobacco and other carcinogens penetrating the mucosa but also the role of higher levels of acetaldehyde as a carcinogenic ingredient in stronger alcoholic beverages (47) .
Other intriguing results from this study are the interactions between the ALDH2 and ADH2 genotypes. On initial examination of this issue, we observed significantly enhanced risks for esophageal cancer among those with the ADH2*1/2*1 genotype throughout all but the ex-drinking category. In addition, the much less active enzyme encoded by ADH2*1/2*1 enhanced the carcinogenic effect of the inactive ALDH2 in a multiplicative fashion. Investigators have found no correlation between the ADH2 genotype and acetaldehydemia (16) . Rather, the presence of the ADH2 isozyme encoded by ADH2*1/2*1 has been associated with slower production of acetaldehyde from ethanol in vitro (8) . This finding refutes the ALDH2-associated hypothesis that acetaldehyde plays a critical role in enhancing esophageal carcinogenesis. We had earlier reported that among Japanese alcoholic men, the much less active form of ADH2 tended to mask alcohol flushing in spite of the presence of inactive ALDH2 and severe acetaldehydemia (15) , and that the less active form of ADH2 increased the carcinogenic effect of inactive ALDH2 on the esophagus (5, 15) . In the present study, we found that individuals (cases and controls) with both ALDH2*1/2*2 and ADH2*1/2*1 genotypes also tended not to experience alcohol flushing, and that those (controls) with the ALDH2*1/2*2 genotype who reported weaker alcohol flushing tended to be heavier drinkers (T. Yokoyama et al., in preparation) . Because the ALDH2 genotype is the basis on which to determine the level of an individual's acetaldehyde exposure after drinking (16) , it may be that the ADH2 genotype affects cancer susceptibility, in part, through its influence on alcohol flushing. If the much less active form of ADH2 diminishes alcohol flushing in ordinary drinkers with inactive ALDH2, the diminished intensity of the protective response may enhance the individual's vulnerability to drinking and his exposure to acetaldehyde. Thus, interactions between the flushing response, ALDH2 and ADH2 genotypes and cancer susceptibility are of great interest for future studies.
Because in the presence of ADH2*1/2*1 the risk for esophageal cancer was higher, even among individuals with ALDH2*1/2*1, the effects of ADH2 cannot be fully explained by the influence of alcohol flushing. We have reported a similarly increased risk for esophageal cancer associated with ADH2*1/2*1 in an alcoholic populations with ALDH2*1/2*1 (5, 15) . Alcoholics with ADH2*1/2*1 tend to have experienced binge drinking and withdrawal syndrome earlier in life than those with other genotypes (51) . Thus, ADH2*1/2*1-mediated acceleration of the occurrence of alcohol-related events may contribute to the enhancement of cancer risk in alcoholics. Some yet unknown differences in esophageal alcohol metabolism or in the drinking behaviors of individuals with and without ADH2*1/2*1 might influence the risk for cancer in the present population. ADH2 is the main enzyme among low-Km class I ADHs expressed in the esophagus (45) . In ADH2*1/2*1 homozygotes, low concentrations of ethanol may linger in the esophageal mucosa during the slow oxidation of low Km ADH2 and thus may be associated with esophageal carcinogenesis.
Increased cancer risks were apparent, though to a lesser extent, in groups of moderate to heavy drinkers with either of the less active enzymes encoded by ADH3*1/3*2 and ADH3*2/ 3*2. Because of the proximity of the ADH2 and ADH3 loci on the human genome, ADH2 gene polymorphism is in linkage disequilibrium with ADH3 gene polymorphism (25, 26) , such that the two less active alleles, ADH2*1 and ADH3*2, are linked. The difference in enzymatic activity between the ADH3*1 and ADH3*2 proteins is estimated to be much smaller than that between the ADH2*1 and ADH2*2 proteins (8). The ADH2*1 and ADH3*2 alleles have been associated with greater risks for alcoholism in east Asians (25, 52) , but when recent Chinese studies considered this linkage disequilibrium, they found no relationship between ADH3 and alcoholism (26, 27) . Therefore, it is reasonable to assume that the ADH3*2 effect on cancer risk also reflects the effects of ADH2*1 through the linkage. Our study also confirmed high linkage disequilibrium statistic D values in both the cancer patients and the controls. The haplotype analysis revealed that ADH2*1 allele was more prevalent in the cancer patients than in controls whether the accompanied ADH3 allele was ADH3*1 or ADH3*2, whereas the prevalence of ADH3*2 allele was similar between the cancer patients and controls when the accompanied ADH2 allele was identical. This clearly indicated that ADH2*1 but not ADH3*2 per se had an individual effect on the risk of cancer. Furthermore, after adjustment for the ALDH2 and ADH2 genotypes, ADH3 showed no significant effects on cancer risk, also suggesting that its linkage with the ADH2 genotype could explain the apparent increase in risk associated with the ADH3 genotype.
Our findings concerning ADH3 are in contrast with those of two European studies, which found that alcoholics possessing the ADH3*1 genotype were at greater risk for upper aerodigestive tract cancer (19, 24) . There is marked racial diversity in ALDH2, ADH2, and ADH3 gene polymorphisms (8) . Europeans' low prevalence of the ALDH2*2 (0%) and ADH2*2 alleles (0-10%) exclude the interactions between ALDH2, ADH2, and ADH3 genotypes. 'At-risk' interactions may also account, in part, for a paradox in Japanese esophageal cancer statistics: due to the high prevalence of the ALDH2*2 and ADH2*2 alleles, per capita alcohol consumption by Japanese is lower than that of Europeans and Americans; however, the death rates for esophageal cancer rank higher for Japanese men than for men from western nations (53) .
There is substantial evidence that smoking (40, 41) and poor intake of vegetables and fruit (54) enhance the risk for esophageal cancer, and our risk estimates were in accord with previous studies. In comparison with the estimated PARs for preference for strong alcoholic beverages (30.7%), smoking (53.6%), and lower intake of green and yellow vegetables (25.7%) and fruit (37.6%), an extraordinarily high proportion of the excessive risk for esophageal cancer in the Japanese men can be attributed to drinking (90.9%), particularly drinking by persons with inactive heterozygous ALDH2 (68.5%). Our moderate-to-heavy drinkers with inactive heterozygous ALDH2, who corresponded to 9.8% of the controls, yielded a PAR of 57.2%.
Our large sample size, which was sufficient for performing subgroup analyses among heavy smokers and non-heavy smokers, showed no significant association between the GSTM1 genotype and the risk for esophageal cancer. The GSTM1 genotype did not appear to play any role in the development of esophageal cancer in this population, a finding that is in accordance with two previous Japanese studies (2, 32) .
Our study has several potential limitations. With any casecontrol study of this type, there is always the risk of population stratification. The controls were recruited from Tokyo, while the cases were recruited from four sites in Japan: three in or near Tokyo (Tokyo, Kanagawa, and Chiba) and one distinct area (Osaka). However, all of the hospitals were located in the urban areas of central portion of Honshu Island. Studies have reported that the frequencies of the ALDH2 and ADH2 genotypes do not differ between the general populations of these areas (2, 6, 14, 18, 25) . The drinking and smoking habits of the general populations are reportedly similar between Tokyo and Osaka (55) . Comparison of drinking, smoking, dietary habits, and ALDH2/ADH2 genotypes of our case populations from the four hospitals showed no significant geographical heterogeneity.
An additional limitation is that the background characteristics might reflect better health among the controls attending the clinics for annual health checkups than actually exists among the general urban population. Estimation of PAR requires that controls be representative of the general popula- tion. According to National Nutrition Survey in Japan in 2000 (56) , a nationwide population-based survey using representative samples, the age-adjusted prevalence of current smokers and the proportion of men who drink alcohol 3 days or more per week and consume at least 1 unit at a time are 37.5% and 55.8%, respectively, in Tokyo. Our study's finding of similar values (40.7% and 56.0%, respectively) for our control group implies that they represented the general population of Tokyo well, at least with regard to drinking and smoking habits.
Because the age distribution of our controls did not match that of the cases well, especially at ages 70-79 years, there was concern that adjustment for age might have unexpected effects. Repeating our analyses and excluding men Ͼ70 years of age confirmed the results obtained in our overall analyses. Nevertheless, these older subgroups deserve further investigation.
Professional and public education about risky conditions connected with inactive ALDH2 is vitally important in a new strategic approach to the prevention of esophageal cancer. The development of screening tests for inactive ALDH2 based on alcohol flushing responses (14, 17, 57) is also important. Because the intensity of the flushing response is decreased in individuals with long or heavy drinking histories, we designed a questionnaire that can detect changes in flushing responses over time, by asking about both current and past flushing (14) . This simple questionnaire has high sensitivity for detecting inactive ALDH2 in men Ͼ50 years old (96.1%; 14) and in patients with esophageal or oropharyngolaryngeal cancer (95.6%; 58). Knowledge of the present findings and use of this highly sensitive flushing questionnaire will benefit many people who can identify their own risks for esophageal cancer. It may also help clinicians diagnose esophageal cancer earlier, by screening the high-risk population.
